Cardiovascular Diabetology

AUGUST 13, 2024

Heart failure with preserved ejection fraction (HFpEF) is associated with systemic inflammation, obesity, metabolic syndrome, and gut microbiome changes. Increased trimethylamine-N-oxide (TMAO) levels are pred.

Preserved Ejection Fraction 103

Preserved Ejection Fraction Heart Failure Obesity Research 103

The New England Journal of Medicine

JANUARY 8, 2025

Heart failure with preserved ejection fraction is noted for symptoms of heart failure, LVEF of at least 50%, and cardiac or structural abnormalities. Treatment includes diuretics and SGLT2 inhibitors.

Preserved Ejection Fraction 74

Preserved Ejection Fraction Heart Failure 74

JAMA Cardiology

DECEMBER 17, 2024

This study assesses the impact of chronic inorganic nitrate administration on exercise tolerance in a larger trial of participants with heart failure with preserved ejection fraction.

Preserved Ejection Fraction 79

Preserved Ejection Fraction Heart Failure Exercise 79

DAIC

MAY 6, 2024

Results of Tenax Therapeutics’ Phase 2 HELP study of levosimendan in patients with pulmonary hypertension (PH) with heart failure with preserved ejection fraction (HFpEF) demonstrated that I.V. Getty Images milla1cf Mon, 05/06/2024 - 10:48 May 6, 2024 — Tenax Therapeutics, Inc. ,

Preserved Ejection Fraction 105

Preserved Ejection Fraction Heart Failure Pulmonary Hypertension 105

Cardiovascular Diabetology

FEBRUARY 6, 2025

The rising prevalence of obesity and its association with heart failure with preserved ejection fraction (HFpEF) highlight an urgent need for a diagnostic approach tailored to this population. Diagnosing HFpEF.

Preserved Ejection Fraction 83

Preserved Ejection Fraction Heart Failure Obesity 83

The New England Journal of Medicine

NOVEMBER 15, 2024

In patients with heart failure with preserved ejection fraction and obesity, treatment with tirzepatide led to a lower risk of death from cardiovascular causes or worsening heart-failure events than placebo.

Preserved Ejection Fraction 75

Preserved Ejection Fraction Heart Failure Obesity 75

Cardiovascular Ultrasound

MARCH 3, 2024

Heart failure with preserved ejection fraction (HFpEF) represents a significant proportion of heart failure cases. Accurate diagnosis is challenging due to the heterogeneous nature of the disease and limitatio.

Preserved Ejection Fraction 95

Preserved Ejection Fraction Heart Failure 95

American College of Cardiology

APRIL 6, 2024

The goal of the STEP-HFpEF DM trial was to compare the safety and efficacy of semaglutide among patients with obesity-related heart failure with preserved ejection fraction (HFpEF) and type 2 diabetes mellitus (DM).

Preserved Ejection Fraction 69

Preserved Ejection Fraction Heart Failure Obesity Diabetes 69

American College of Cardiology

NOVEMBER 7, 2024

The goal of the EMPEROR-Preserved trial was to assess the safety and efficacy of empagliflozin in patients with symptomatic heart failure with preserved ejection fraction (HFpEF), irrespective of diabetes status.

Preserved Ejection Fraction 64

Preserved Ejection Fraction Heart Failure Diabetes Outcomes 64

DAIC

MARCH 25, 2025

25 include Efficacy and safety of finerenone across the spectrum of kidney risk in heart failure with mildly reduced or preserved ejection fraction during the session;"Innovations and Insights in Heart Failure With Preserved Ejection Fraction: Emerging Therapies, Biomarkers and Mechanistic Studies."

52

52

The New England Journal of Medicine

JANUARY 29, 2025

Treatment options for heart failure with preserved ejection fraction have historically been limited. In a 2016 review of this condition in the Journal, treatment recommendations focused on diuretics, exercise training, and management of coexisting conditions.1

Preserved Ejection Fraction 59

Preserved Ejection Fraction Heart Failure Exercise 59

JAMA Cardiology

APRIL 23, 2024

This systematic review and meta-analysis investigates the efficacy of catheter ablation compared with rate or rhythm control among patients with atrial fibrillation and heart failure.

Preserved Ejection Fraction 99

Preserved Ejection Fraction Atrial Fibrillation Heart Failure Ablation 99

American College of Cardiology

JULY 29, 2024

The goal of the CAMEO-DAPA trial was to assess whether dapagliflozin, a sodium-glucose cotransporter-2 inhibitor (SGLT2i), affects rest and exercise pulmonary capillary wedge pressure (PCWP) in patients with heart failure with preserved ejection fraction (HFpEF).

Preserved Ejection Fraction 61

Preserved Ejection Fraction Heart Failure Exercise Pulmonary 61

Cardiovascular Diabetology

MARCH 21, 2025

Heart failure (HF) with preserved ejection fraction (HFpEF) is increasingly prevalent worldwide due to aging and comorbidities. Epicardial adipose tissue (EAT), favored by diabetes and obesity, was shown to co.

Preserved Ejection Fraction 52

Preserved Ejection Fraction Heart Failure Obesity Diabetes 52

Journal of Clinical Investigation - Cardiology

DECEMBER 15, 2023

Heart failure with preserved ejection fraction (HFpEF) is a widespread syndrome with limited therapeutic options and poorly understood immune pathophysiology.

Preserved Ejection Fraction 75

Preserved Ejection Fraction Heart Failure Obesity Ablation 75

American College of Cardiology

JULY 8, 2024

The goal of the PARAGON-HF trial was to evaluate the neprilysin-angiotension receptor inhibitor sacubitril/valsartan among patients with heart failure with preserved ejection fraction (HFpEF).

Preserved Ejection Fraction 56

Preserved Ejection Fraction Heart Failure Outcomes Article 56

Medical Xpress - Cardiology

JULY 29, 2024

A novel study co-authored by a heart failure cardiologist at University Hospitals Harrington Heart & Vascular Institute demonstrates the effectiveness of a newly developed scoring system in identifying patients with Heart Failure with Preserved Ejection Fraction (HFpEF).

Preserved Ejection Fraction 111

Preserved Ejection Fraction Heart Failure Research Hospital 111

Frontiers in Cardiovascular Medicine

NOVEMBER 17, 2024

However, its role in right ventricular (RV) function has not been evaluated.MethodsWe retrospectively analyzed the electronic medical data of 1,014 Heart Failure with Preserved Ejection Fraction (HFpEF) patients to evaluate the relationship between anemia and RV dysfunction in patients with HFpEF and whether this relationship is influenced by classical (..)

Preserved Ejection Fraction 59

Preserved Ejection Fraction Heart Failure Tricuspid Atrial Fibrillation 59

Science Daily - Heart Disease

SEPTEMBER 2, 2024

Finerenone reduced the composite of total first and recurrent heart failure (HF) events (hospitalizations for HF or urgent HF visits) and cardiovascular death in patients with HF and mildly reduced or preserved ejection fraction, according to an international clinical trial.

Preserved Ejection Fraction 123

Preserved Ejection Fraction Heart Failure Hospital 123

Journal of the American Heart Association

DECEMBER 14, 2024

ConclusionsEAT accumulation is associated with an adverse prognosis in patients with HF with midrange ejection fraction and those with HF with preserved ejection fraction. In addition, EAT provides incremental prognostic value beyond left ventricular ejection fraction and New York Heart Association class.

Preserved Ejection Fraction 58

Preserved Ejection Fraction Heart Failure Hospital Outcomes 58

Science Daily - Heart Disease

AUGUST 1, 2024

A new small study has revealed the impact of obesity on muscle structure in patients having a form of heart failure called heart failure with a preserved ejection fraction (HFpEF).

Heart Failure 118

Heart Failure Preserved Ejection Fraction Obesity 118

Science Daily - Heart Disease

JULY 24, 2024

In mice with heart failure with preserved ejection fraction (HFpEF), increasing ketone supply to the heart allowed their hearts to utilize more ketones and produce more energy.

Preserved Ejection Fraction 114

Preserved Ejection Fraction Diabetes Heart Failure 114

Cardiovascular Diabetology

NOVEMBER 4, 2024

Aging is influenced by genetic determinants and comorbidities, among which diabetes increases the risk for heart failure with preserved ejection fraction. There is no therapy to prevent heart dysfunction in ag.

Preserved Ejection Fraction 52

Preserved Ejection Fraction Cardiac Function Heart Dysfunction Heart Failure 52

JAMA Cardiology

JULY 23, 2024

This randomized clinical trial investigates the effect of dapagliflozin on right ventricular performance and vascular load during exertion in heart failure with preserved ejection fraction (HFpEF).

Preserved Ejection Fraction 111

Preserved Ejection Fraction Pulmonary Heart Failure 111

American Heart News - Heart News

JULY 24, 2024

Research Highlights: In mice with heart failure with preserved ejection fraction (HFpEF), increasing ketone supply to the heart allowed their hearts to utilize more ketones and produce more energy. Researchers hope this study may help to improve our.

Preserved Ejection Fraction 114

Preserved Ejection Fraction Heart Failure Research 114

Science Daily - Heart Disease

JULY 29, 2024

A novel study co-authored by a heart failure cardiologist demonstrates the effectiveness of a newly developed scoring system in identifying patients with Heart Failure with Preserved Ejection Fraction (HFpEF).

Preserved Ejection Fraction 111

Preserved Ejection Fraction Heart Failure 111

Cardiovascular Diabetology

AUGUST 30, 2024

Heart failure with preserved ejection fraction (HFpEF) is common in type 2 diabetes mellitus (T2D), leading to high morbidity and mortality. Managing HFpEF in diabetic patients is challenging with limited trea.

Preserved Ejection Fraction 59

Preserved Ejection Fraction Heart Failure Diabetes Research 59

JAMA Cardiology

SEPTEMBER 29, 2024

The EMBARK-HFpEF multicenter, open-label trial examines the effects of cardiac myosin inhibition with mavacamten in patients with heart failure with preserved ejection fraction with a left ventricular ejection fraction of 60% or greater.

Preserved Ejection Fraction 111

Preserved Ejection Fraction Heart Failure 111

Med Page Today

NOVEMBER 16, 2024

(MedPage Today) -- CHICAGO -- A long-acting GIP/GLP-1 receptor agonist conferred significant clinical benefit for people with obesity and accompanying heart failure with preserved ejection fraction (HFpEF), according to the SUMMIT trial. Incident.

Preserved Ejection Fraction 111

Preserved Ejection Fraction Heart Failure Obesity 111

Frontiers in Cardiovascular Medicine

JANUARY 7, 2024

Heart failure with preserved ejection fraction (HFpEF) is the largest unmet clinical need in cardiovascular medicine. Despite decades of research, the treatment option for HFpEF is still limited, indicating our ongoing incomplete understanding on the underlying molecular mechanisms.

Preserved Ejection Fraction 59

Preserved Ejection Fraction Heart Failure Biomarkers Cardiovascular Disease 59

American College of Cardiology

NOVEMBER 16, 2024

The goal of the SUMMIT trial was to compare the safety and efficacy of tirzepatide among patients with heart failure with preserved ejection fraction (HFpEF) and obesity.

Preserved Ejection Fraction 49

Preserved Ejection Fraction Heart Failure Obesity Article 49

Science Daily - Heart Disease

MAY 30, 2024

A mouse study of heart failure with preserved ejection fraction (HFpEF) found male-female differences at the cellular level. The findings could have implications for how HFpEF is treated in women compared to men.

Preserved Ejection Fraction 107

Preserved Ejection Fraction Heart Failure 107

JAMA Cardiology

SEPTEMBER 26, 2024

This prespecified analysis of the Finerenone Trial to Investigate the Efficacy and Safety Superior to Placebo in Patients With Heart Failure (FINEARTS-HF) randomized clinical trial investigates the long-term effects of treatment with the nonsteroidal mineralocorticoid receptor antagonist, finerenone, in patients with heart failure with mildly reduced (..)

Heart Failure 111

Heart Failure Preserved Ejection Fraction 111

Medical Xpress - Cardiology

NOVEMBER 25, 2024

Heart failure with preserved ejection fraction (HFpEF) is underdiagnosed in patients with severe secondary tricuspid regurgitation (STR) of undefined etiology (isolated STR), according to a study published online Nov. 6 in JAMA Cardiology.

Preserved Ejection Fraction 40

Preserved Ejection Fraction Heart Failure Tricuspid 40

Med Page Today

OCTOBER 2, 2024

(MedPage Today) -- The novel investigational weight loss agent HU6 had mixed results specifically targeting obesity-related heart failure with preserved ejection fraction (HFpEF), based on the small HuMain-HFpEF trial. After 19 weeks on daily.

Preserved Ejection Fraction 105

Preserved Ejection Fraction Obesity Heart Failure 105

American Heart News - Heart News

NOVEMBER 16, 2024

called SUMMIT, participants with heart failure with preserved ejection fraction (HFpEF) and obesity taking tirzepatide for an average of 2 years had. Research Highlights: In an international trial of 713 adults in nine countries including the U.S.

Preserved Ejection Fraction 103

Preserved Ejection Fraction Heart Failure Obesity Research 103

Medical Xpress - Cardiology

OCTOBER 10, 2024

Mavacamten, a drug initially developed to treat hypertrophic cardiomyopathy, has shown signs of reducing heart stress in patients with heart failure with preserved ejection fraction.

Preserved Ejection Fraction 99

Preserved Ejection Fraction Biomarkers Heart Failure Cardiomyopathy 99